Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Rating)’s stock price rose 0.6% on Friday . The stock traded as high as $1.84 and last traded at $1.75. Approximately 92,441 shares traded hands during trading, a decline of 96% from the average daily volume of 2,507,970 shares. The stock had previously closed at $1.74.
Shuttle Pharmaceuticals Stock Up 0.6 %
The company has a 50-day moving average of $6.11.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter worth approximately $67,000. Virtu Financial LLC acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at $78,000. Jane Street Group LLC acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at $96,000. Two Sigma Investments LP acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at $151,000. Finally, UBS Group AG acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at $156,000.
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc, through its subsidiary, Shuttle Pharmaceuticals, Inc, focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers.
- Get a free copy of the StockNews.com research report on Shuttle Pharmaceuticals (SHPH)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.